Applied Spectral Imaging
Private Company
Total funding raised: $19.5M
Overview
Applied Spectral Imaging is a long-established, revenue-generating private company specializing in digital diagnostic solutions for cytogenetics and pathology. Its core technology encompasses automated slide scanning, image analysis, and workflow software for fluorescence and brightfield imaging, serving clinical and research laboratories. As a subsidiary of ZYTOMICS, ASI leverages combined expertise in imaging and reagents to offer integrated end-to-end laboratory solutions. The company holds FDA clearances and IVDR compliance, with a strong international distribution network supporting its commercial operations.
Technology Platform
Scanner-agnostic and probe-agnostic software and hardware platforms for digital cytogenetics (karyotyping, FISH) and digital pathology (H&E, IHC). Supports brightfield, fluorescence, and spectral imaging with automated analysis, workflow management, and LIS integration.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
ASI competes in the digital pathology and cytogenetics software market against major players like Roche (Ventana), Philips, Leica Biosystems, and Akoya Biosciences, as well as specialized software companies. Its key differentiator is a scanner-agnostic and probe-agnostic open platform, providing labs with flexibility compared to closed, proprietary ecosystems.